Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drupacine as a potent SARS-CoV-2 replication inhibitor in vitro

3 Sept 2024

Abstract excerpt

• Scientific question : The continued emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the limitations of current antiviral treatments underscore the need for novel and potent antiviral therapies. We aim to discover novel antivirals against SARS-CoV-2 infection. • Evidence before this study : Previous research has established a transcription and replication-competent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to SARS-CoV-2 and COVID-19 Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40078736
DOI: 10.1016/j.bsheal.2024.09.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drupacine as a potent SARS-CoV-2 replication inhibitor in vitroPMID 40078736Read ↗

Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In VitroSemantic proximity Read ↗

Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testingSemantic proximity Read ↗

RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic targetSemantic proximity Read ↗

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitroSemantic proximity Read ↗

SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19Semantic proximity Read ↗

SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay SystemSemantic proximity Read ↗

Inhibitors of SARS-CoV‑2 Entry: Current and Future OpportunitiesSemantic proximity Read ↗

Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymeraseSemantic proximity Read ↗

SARS-CoV-2 replicon for high-throughput antiviral screeningSemantic proximity Read ↗

An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challengesSemantic proximity Read ↗

Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assaySemantic proximity Read ↗

Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.